EQS-News: Symrise AG / Schlagwort(e): Jahresergebnis Symrise erhöht Dividende und bekräftigt Ausblick 27.03.2025 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Pressemitteilung — Holzminden, 27. März 2025 Symrise erhöht Dividende und bekräftigt Ausblick Dividendenvorschlag von 1,20 € je Aktie (2023: 1,10 €) - 15. Erhöhung in Folge Symrise bekräftigt Jahresziele 2025: Organisches Wachstum von 5-7 % Die Profitabilität (EBITDA-Marge) soll um die 21 % betragen Vertrag von Dr. Stephanie Coßmann...
EQS-News: Symrise AG / Key word(s): Annual Results Symrise raises dividend and confirms outlook 27.03.2025 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release — Holzminden, March 27, 2025 Symrise raises dividend and confirms outlook Dividend proposal of € 1.20 per share (2023: € 1.10) – 15th increase in succession Symrise confirms targets for 2025: Organic growth of 5-7 % Profitability (EBITDA margin) of around 21 % expected Executive Board contract of Dr. Stephanie Cossmann extended ah...
EQS-News: Symrise AG / Key word(s): Agreement Symrise accelerates in Human Health and Pet Nutrition through a strategic partnership with HBC 21.02.2025 / 10:15 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release — Holzminden, 21 February 2025 Symrise accelerates in Human Health and Pet Nutrition through a strategic partnership with HBC This partnership ideally complements Symrise’s current portfolio with clinically proven marine ingredients HBC, a leading manufacturer of human grade, sustainable marine proteins, collagens and oi...
A director at Symrise AG bought 210 shares at 95.780EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...
EQS-News: Symrise AG / Schlagwort(e): Vorläufiges Ergebnis Symrise erzielt 2024 deutliches Umsatzplus bei stark gestiegener Profitabilität (News mit Zusatzmaterial) 30.01.2025 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Pressemitteilung — Holzminden, 30. Januar 2025 Vorläufige Finanzergebnisse 2024 Organisches Wachstum von 8,7 % / Konzernumsatz steigt um 5,7 % auf rund 5 Mrd. € (2023: 4.7 Mrd. €) ...
EQS-News: Symrise AG / Key word(s): Preliminary Results Symrise achieves significant sales growth in 2024 with a strong increase in profitability (news with additional features) 30.01.2025 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press release — Holzminden, January 30, 2025 Preliminary financial results 2024 Organic growth of 8.7% / Group sales increase by 5.7% to around €5 billion (2023: €4.7 billion) EBITDA of €1,033 million significantly above previous year's figure (2023: €903 million1) EBITDA margin...
We are hosting our 27th German Investment Seminar in New York from 13 to 15 January 2025. In total, 66 companies are participating. Below, we provide some of our initial feedback on the companies, which were present on day one. Among these companies which were presented during the first day, we notably highlight a positive feedback on BASF, Fresenius Medical Care and Merck AG. We also keep our positive ratings on stocks like Commerzbank, Deutsche Telekom and Schaeffler. We maintain our underperf...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.